Payment overview · 2025
General Payments
$520,657.26
833 reported records · 16 companies
Healthcare provider profile · identity verified
Robert Oliver Morton, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · ADA, OK · NPI 1336222504
Verified facts
What the public records show
CMS Open Payments records show Robert Oliver Morton, MD received $520,657.26 in general payments during 2025 across 833 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 25.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abilify Maintena, Aristada, Austedo Xr, Caplyta, Cobenfy, Fanapt, Ingrezza, Invega Sustenna, Invega Trinza, Lybalvi, Nuplazid, Qelbree, Rexulti, Trintellix, Uzedy, Vivitrol, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 242 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 2852 claims for Vraylar by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 414 claims for Nuplazid by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 494 claims for Aristada by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 705 claims for Lybalvi by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIVITROL as an associated drug or biological on 9533 records involving 5661 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vivitrol by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported COBENFY as an associated drug or biological on 92858 records involving 21456 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Cobenfy by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 231 claims for Eliquis by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 854 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 854 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 396 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA TRINZA as an associated drug or biological on 8191 records involving 2146 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Invega Trinza by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Xarelto by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 460 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 874 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 508 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 460 claims for Rexulti by this doctor in 2024.
Supernus Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Qelbree as an associated drug or biological on 61278 records involving 18421 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Qelbree by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 3432 claims for Trintellix by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 360 claims for Austedo by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 642 claims for Austedo Xr by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UZEDY as an associated drug or biological on 46702 records involving 13355 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Uzedy by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Briviact by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Fanapt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $133,260.39 | 25.6% | 235 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $116,554.34 | 22.4% | 112 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $96,023.13 | 18.4% | 151 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $76,378.05 | 14.7% | 99 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $33,291.44 | 6.4% | 52 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $26,472.93 | 5.1% | 45 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16,386.59 | 3.1% | 35 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $12,216.94 | 2.4% | 29 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $9,377.24 | 1.8% | 40 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $178.18 | 0.0% | 10 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $177.71 | 0.0% | 10 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $171.67 | 0.0% | 6 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $95.28 | 0.0% | 5 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $44.25 | 0.0% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $15.05 | 0.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14.07 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $420,237.50 | 131 |
| Consulting Fee | $50,486.25 | 14 |
| Travel and Lodging | $36,017.95 | 166 |
| Food and Beverage | $13,680.41 | 516 |
| Education | $235.15 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $110,866.85 | 206 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $96,023.13 | 151 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $76,378.05 | 99 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $58,453.83 | 57 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $57,891.03 | 53 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $33,230.53 | 51 | 2025 |
Source payment records
|
|||||
| INVEGA TRINZA Normalized: invega trinza |
Drug | Janssen Pharmaceuticals, Inc | $32,764.49 | 26 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $26,347.96 | 38 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $16,488.05 | 42 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $12,216.94 | 29 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $9,377.24 | 40 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $181.38 | 11 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $178.18 | 10 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $171.67 | 6 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $113.24 | 6 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $95.28 | 5 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $76.25 | 3 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $76.25 | 3 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $44.25 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $15.05 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA INITIO Normalized: aristada initio |
Drug | Alkermes, Inc. | $11.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABILIFY MAINTENA abilify maintena |
2025 | Abilify Maintena | 2024 | 117 | exact normalized | Medicare Part D |
| ARISTADA aristada |
2025 | Aristada | 2024 | 494 | exact normalized | Medicare Part D |
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 642 | exact normalized | Medicare Part D |
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 854 | exact normalized | Medicare Part D |
| COBENFY cobenfy |
2025 | Cobenfy | 2024 | 124 | exact normalized | Medicare Part D |
| FANAPT fanapt |
2025 | Fanapt | 2024 | 121 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 874 | exact normalized | Medicare Part D |
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 396 | exact normalized | Medicare Part D |
| INVEGA TRINZA invega trinza |
2025 | Invega Trinza | 2024 | 28 | exact normalized | Medicare Part D |
| LYBALVI lybalvi |
2025 | Lybalvi | 2024 | 705 | exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 414 | exact normalized | Medicare Part D |
| Qelbree qelbree |
2025 | Qelbree | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 460 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 3432 | exact normalized | Medicare Part D |
| UZEDY uzedy |
2025 | Uzedy | 2024 | 38 | exact normalized | Medicare Part D |
| VIVITROL vivitrol |
2025 | Vivitrol | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 2852 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
242 | 29 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
2852 | 289 |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
414 | 39 |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | ARISTADA open payments reported associated product |
CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566 |
Aristada · 2024 Exact normalized brand match · 1 Part D row |
494 | 66 |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
705 | 81 |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | VIVITROL open payments reported associated product |
CMS Open Payments — General Payments 9533 supporting records · 5661 recipient NPIs · example record 1222428584 |
Vivitrol · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | COBENFY open payments reported associated product |
CMS Open Payments — General Payments 92858 supporting records · 21456 recipient NPIs · example record 1184377695 |
Cobenfy · 2024 Exact normalized brand match · 1 Part D row |
124 | 68 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
231 | 27 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
854 | 90 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | Caplyta open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
854 | 90 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
396 | 62 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA TRINZA open payments reported associated product |
CMS Open Payments — General Payments 8191 supporting records · 2146 recipient NPIs · example record 1174223262 |
Invega Trinza · 2024 Exact normalized brand match · 1 Part D row |
28 | 12 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
117 | 18 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
460 | 53 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
874 | 114 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
117 | 18 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
508 | 41 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
460 | 53 |
| Supernus Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | Qelbree open payments reported associated product |
CMS Open Payments — General Payments 61278 supporting records · 18421 recipient NPIs · example record 1244861775 |
Qelbree · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
3432 | 347 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
360 | 35 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
642 | 65 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | UZEDY open payments reported associated product |
CMS Open Payments — General Payments 46702 supporting records · 13355 recipient NPIs · example record 1247244226 |
Uzedy · 2024 Exact normalized brand match · 1 Part D row |
38 | 14 |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
183 | 23 |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | FANAPT open payments reported associated product |
CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535 |
Fanapt · 2024 Exact normalized brand match · 1 Part D row |
121 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clozapine | Clozapine | 10076 | 611 |
| Escitalopram Oxalate | Escitalopram Oxalate | 7613 | 814 |
| Riluzole | Riluzole | 5861 | 631 |
| Olanzapine | Olanzapine | 5188 | 556 |
| Clonidine Hcl | Clonidine Hcl | 4851 | 538 |
| Lamotrigine | Lamotrigine | 3616 | 367 |
| Trintellix | Vortioxetine Hydrobromide | 3432 | 347 |
| Metformin Hcl | Metformin Hcl | 3046 | 369 |
| Memantine Hcl | Memantine Hcl | 2971 | 373 |
| Vraylar | Cariprazine Hcl | 2852 | 289 |
| Naltrexone Hcl | Naltrexone Hcl | 2781 | 285 |
| Risperidone | Risperidone | 2305 | 251 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1958 | 243 |
| Propranolol Hcl | Propranolol Hcl | 1821 | 206 |
| Ramelteon | Ramelteon | 1806 | 227 |
| Lithium Carbonate | Lithium Carbonate | 1796 | 173 |
| Pindolol | Pindolol | 1742 | 199 |
| Donepezil Hcl | Donepezil Hcl | 1625 | 245 |
| Sertraline Hcl | Sertraline Hcl | 1411 | 151 |
| Mirtazapine | Mirtazapine | 1392 | 207 |
| Lurasidone Hcl | Lurasidone Hcl | 1234 | 154 |
| Trazodone Hcl | Trazodone Hcl | 1234 | 165 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1211 | 159 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1000 | 120 |
| Quetiapine Fumarate | Quetiapine Fumarate | 980 | 100 |
| Levetiracetam | Levetiracetam | 909 | 89 |
| Gabapentin | Gabapentin | 887 | 145 |
| Ingrezza | Valbenazine Tosylate | 874 | 114 |
| Aripiprazole | Aripiprazole | 863 | 116 |
| Caplyta | Lumateperone Tosylate | 854 | 90 |
| Duloxetine Hcl | Duloxetine Hcl | 853 | 97 |
| Divalproex Sodium Er | Divalproex Sodium | 842 | 86 |
| Prazosin Hcl | Prazosin Hcl | 814 | 92 |
| Doxazosin Mesylate | Doxazosin Mesylate | 803 | 78 |
| Desmopressin Acetate | Desmopressin Acetate | 752 | 75 |
| Divalproex Sodium | Divalproex Sodium | 716 | 89 |
| Lybalvi | Olanzapine/Samidorphan Malate | 705 | 81 |
| Topiramate | Topiramate | 690 | 83 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 686 | 117 |
| Glycopyrrolate | Glycopyrrolate | 680 | 73 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 647 | 87 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 647 | 66 |
| Austedo Xr | Deutetrabenazine | 642 | 65 |
| Oxcarbazepine | Oxcarbazepine | 628 | 63 |
| Famotidine | Famotidine | 599 | 81 |
| Fluticasone Propionate | Fluticasone Propionate | 554 | 136 |
| Lorazepam | Lorazepam | 553 | 64 |
| Bupropion Xl | Bupropion Hcl | 544 | 64 |
| Lisinopril | Lisinopril | 542 | 68 |
| Losartan Potassium | Losartan Potassium | 537 | 95 |
| Trulicity | Dulaglutide | 536 | 70 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 508 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 500 | 64 |
| Aristada | Aripiprazole Lauroxil | 494 | 66 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 486 | 91 |
| Meloxicam | Meloxicam | 484 | 80 |
| Ozempic | Semaglutide | 484 | 59 |
| Potassium Chloride | Potassium Chloride | 468 | 69 |
| Rexulti | Brexpiprazole | 460 | 53 |
| Belsomra | Suvorexant | 437 | 58 |
| Benztropine Mesylate | Benztropine Mesylate | 419 | 63 |
| Omeprazole | Omeprazole | 417 | 43 |
| Nuplazid | Pimavanserin Tartrate | 414 | 39 |
| Invega Sustenna | Paliperidone Palmitate | 396 | 62 |
| Gemtesa | Vibegron | 394 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 388 | 50 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 382 | 48 |
| Clonazepam | Clonazepam | 375 | 62 |
| Molindone Hcl | Molindone Hcl | 367 | 49 |
| Buspirone Hcl | Buspirone Hcl | 366 | 56 |
| Austedo | Deutetrabenazine | 360 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 347 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 347 | 36 |
| Clozapine Odt | Clozapine | 343 | 44 |
| Furosemide | Furosemide | 337 | 48 |
| Memantine Hcl Er | Memantine Hcl | 307 | 31 |
| Haloperidol | Haloperidol | 281 | 29 |
| Ziprasidone Hcl | Ziprasidone Hcl | 261 | 27 |
| Linzess | Linaclotide | 242 | 29 |
| Auvelity | Dextromethorphan Hbr/Bupropion | 240 | 29 |
| Eliquis | Apixaban | 231 | 27 |
| Myrbetriq | Mirabegron | 223 | 17 |
| Lithium Carbonate Er | Lithium Carbonate | 222 | 23 |
| Allopurinol | Allopurinol | 218 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 198 | 27 |
| Amlodipine Besylate | Amlodipine Besylate | 195 | 39 |
| Paliperidone Er | Paliperidone | 194 | 20 |
| Glipizide | Glipizide | 192 | 29 |
| Sucralfate | Sucralfate | 189 | 25 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 186 | 20 |
| Amantadine | Amantadine Hcl | 183 | 24 |
| Briviact | Brivaracetam | 183 | 23 |
| Solifenacin Succinate | Solifenacin Succinate | 174 | 25 |
| Guanfacine Hcl Er | Guanfacine Hcl | 172 | 17 |
| Lacosamide | Lacosamide | 168 | 20 |
| Atomoxetine Hcl | Atomoxetine Hcl | 165 | 21 |
| Vilazodone Hcl | Vilazodone Hcl | 149 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 147 | 25 |
| Fenofibrate | Fenofibrate Nanocrystallized | 144 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 129 | 17 |
| Baclofen | Baclofen | 124 | 19 |
| Cobenfy | Xanomeline Tart/Trospium Chlor | 124 | 68 |
| Fanapt | Iloperidone | 121 | 13 |
| Naproxen | Naproxen | 119 | 21 |
| Enulose | Lactulose | 118 | 34 |
| Abilify Maintena | Aripiprazole | 117 | 18 |
| Carbamazepine | Carbamazepine | 117 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 116 | 15 |
| Minocycline Hcl | Minocycline Hcl | 113 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 109 | 21 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 107 | 19 |
| Carvedilol | Carvedilol | 106 | 19 |
| Clomipramine Hcl | Clomipramine Hcl | 98 | 11 |
| Rozerem | Ramelteon | 98 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 18 |
| Pregabalin | Pregabalin | 92 | 16 |
| Doxepin Hcl | Doxepin Hcl | 91 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 90 | 18 |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 89 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 89 | 11 |
| Simvastatin | Simvastatin | 89 | suppressed |
| Latanoprost | Latanoprost | 88 | 15 |
| Rybelsus | Semaglutide | 86 | suppressed |
| Torsemide | Torsemide | 85 | 12 |
| Bumetanide | Bumetanide | 83 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 83 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 81 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 22 |
| Montelukast Sodium | Montelukast Sodium | 79 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 77 | 37 |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 71 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 71 | suppressed |
| Lactulose | Lactulose | 69 | 18 |
| Metformin Hcl Er | Metformin Hcl | 69 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 69 | suppressed |
| Trospium Chloride | Trospium Chloride | 68 | 33 |
| Alogliptin | Alogliptin Benzoate | 65 | suppressed |
| Azithromycin | Azithromycin | 65 | 55 |
| Xarelto | Rivaroxaban | 64 | suppressed |
| Carbamazepine Er | Carbamazepine | 63 | suppressed |
| Spironolactone | Spironolactone | 63 | 12 |
| Tramadol Hcl | Tramadol Hcl | 61 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 26 |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 60 | 12 |
| Tradjenta | Linagliptin | 60 | suppressed |
| Ibuprofen | Ibuprofen | 58 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 58 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 56 | suppressed |
| Mounjaro | Tirzepatide | 56 | suppressed |
| Finasteride | Finasteride | 55 | suppressed |
| Clonidine | Clonidine | 54 | suppressed |
| Constulose | Lactulose | 54 | suppressed |
| Hydrocortisone | Hydrocortisone | 54 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 54 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 22 |
| Atropine Sulfate | Atropine Sulfate | 50 | 17 |
| Armodafinil | Armodafinil | 48 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 46 | 12 |
| Prednisone | Prednisone | 46 | 21 |
| Haloperidol Decanoate | Haloperidol Decanoate | 45 | suppressed |
| Novolog Flexpen | Insulin Aspart | 45 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 44 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 18 |
| Propranolol Hcl Er | Propranolol Hcl | 44 | suppressed |
| Jardiance | Empagliflozin | 43 | suppressed |
| Ezetimibe | Ezetimibe | 41 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | suppressed |
| Valproic Acid | Valproic Acid | 41 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 40 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 40 | suppressed |
| Scopolamine | Scopolamine | 39 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 38 | 12 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 38 | suppressed |
| Uzedy | Risperidone | 38 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 37 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 36 | 12 |
| Imipramine Hcl | Imipramine Hcl | 36 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 35 | 12 |
| Midodrine Hcl | Midodrine Hcl | 34 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | suppressed |
| Estradiol | Estradiol | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Mupirocin | Mupirocin | 31 | 22 |
| Ondansetron Odt | Ondansetron | 31 | 16 |
| Primidone | Primidone | 31 | suppressed |
| Vascepa | Icosapent Ethyl | 31 | suppressed |
| Zonisamide | Zonisamide | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 30 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 20 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 29 | 11 |
| Lubiprostone | Lubiprostone | 29 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 29 | suppressed |
| Dayvigo | Lemborexant | 28 | suppressed |
| Invega Trinza | Paliperidone Palmitate | 28 | 12 |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 28 | suppressed |
| Modafinil | Modafinil | 28 | suppressed |
| Thioridazine Hcl | Thioridazine Hcl | 28 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 27 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 27 | suppressed |
| Nystop | Nystatin | 27 | 14 |
| Humulin R | Insulin Regular, Human | 26 | suppressed |
| Loperamide | Loperamide Hcl | 26 | 11 |
| Qulipta | Atogepant | 26 | suppressed |
| Rivastigmine | Rivastigmine | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Letrozole | Letrozole | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 23 | suppressed |
| Loxapine | Loxapine Succinate | 22 | suppressed |
| Qelbree | Viloxazine Hcl | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Lumigan | Bimatoprost | 21 | suppressed |
| Mono-Linyah | Norgestimate-Ethinyl Estradiol | 21 | suppressed |
| Novolog | Insulin Aspart | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 16 |
| Glipizide Er | Glipizide | 20 | suppressed |
| Olanzapine Odt | Olanzapine | 20 | suppressed |
| Acamprosate Calcium | Acamprosate Calcium | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Humalog | Insulin Lispro | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Acetic Acid | Acetic Acid | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 16 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | 11 |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Clobazam | Clobazam | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 15 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Vivitrol | Naltrexone Microspheres | 15 | suppressed |
| Admelog | Insulin Lispro | 14 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Aviane | Levonorgestrel/Ethin.Estradiol | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Restasis | Cyclosporine | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Calcium Acetate | Calcium Acetate | 13 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Lamotrigine Odt | Lamotrigine | 13 | suppressed |
| Nystatin | Nystatin | 13 | 11 |
| Perphenazine | Perphenazine | 13 | suppressed |
| Semglee (Yfgn) | Insulin Glargine-Yfgn | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Entacapone | Entacapone | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Ongentys | Opicapone | 12 | suppressed |
| Tri-Mili | Norgestimate-Ethinyl Estradiol | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Captopril | Captopril | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Thiothixene | Thiothixene | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $520,657.26 · 833 records | E.R. Squibb & Sons, L.L.C. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, ARISTADA INITIO, AUSTEDO XR, CAPLYTA, COBENFY, FANAPT, Fintepla, INGREZZA, INVEGA SUSTENNA, INVEGA TRINZA, Jornay PM, LYBALVI, NUPLAZID, Qelbree, REXULTI, TRINTELLIX, UZEDY, VIVITROL, VRAYLAR, WAKIX | 28 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abilify Maintena play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error